Clinical trial

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

NCT02632747

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-05-10

PhasePHASE2

Study timeline

Study start (actual)2016-05-10Date precision: day

Registry last updated2020-07-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 1unresolved

Diabetes Mellitus, Type 2unresolved

Obesityunresolved

Interventions

EmpagliflozinDRUG

Placebo (matching empagliflozin)DRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02632747 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.